title: Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells.
authors.affiliation: Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Norris
authors.affiliation: Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
authors.forename: D
authors.initials: D
authors.lastname: DeStephanis
authors.affiliation: Array BioPharma Inc., Boulder, CO, USA.
authors.forename: B
authors.initials: B
authors.lastname: Tunquist
authors.affiliation: Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.
authors.forename: S
authors.initials: S
authors.lastname: Usmani
authors.affiliation: Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
authors.forename: R
authors.initials: R
authors.lastname: Ganapathi
authors.affiliation: Department of Cancer Pharmacology, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
authors.forename: M
authors.initials: M
authors.lastname: Ganapathi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000494:pharmacology; D064592:Autografts; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage* / Q000494:pharmacology; D009101:Multiple Myeloma / Q000473:pathology / Q000628:therapy*; D013830:Thiadiazoles / Q000008:administration & dosage* / Q000494:pharmacology; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D013830:Thiadiazoles; C544550:filanesib; D008558:Melphalan